
    
      A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel
      Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8
      Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight
      Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM).
    
  